Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.

Sponsoren

Hauptsponsor: Bayer

Quelle Bayer
Kurze Zusammenfassung

The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.

Gesamtstatus Completed
Anfangsdatum December 2002
Fertigstellungstermin March 2005
Primäres Abschlussdatum March 2005
Phase Phase 1/Phase 2
Studientyp Interventional
Einschreibung 56
Bedingung
Intervention

Interventionsart: Drug

Interventionsname: Interleukin-2 SA

Beschreibung: HAART and Bay 50-4798

Armgruppenetikett: Arm 1

Interventionsart: Drug

Interventionsname: HAART

Beschreibung: HAART alone

Armgruppenetikett: Arm 2

Teilnahmeberechtigung

Kriterien:

Inclusion Criteria:

- Documented HIV infection (positive enzyme linked immuno assay (EIA) confirmed by Western Blot).

- Age greater than or equal to 18 years.

- Plasma HIV viral load less than 10,000 copies/ml (by bDNA assay or less than 14,000 copies/ml by RT-PCR) on at least 2 occasions within 8 weeks prior to study entry with no more than a 0.5 log increase between the most recent and the earlier viral load measurements.

- CD4 + T-cell count greater than or equal to 200/mm(3) on at least 2 occasions within 8 weeks of study entry.

- On a stable HAART regimen for greater than or equal to 8 weeks.

- Karnofsky Score greater than or equal to 80.

- Written informed consent. Exclusion Criteria:

- Prior treatment with IL-2 or an IL-2 analogue.

- Pregnancy or breastfeeding. - Use of any known immunomodulators, cytokines, growth factors or systemic corticosteroids (e.g. prednisone greater than or equal to 15 mg/day or equivalent) within 4 weeks prior to study enrollment.

- History of an AIDS defining illness by the Centers for Disease Control (CDC) definition within 8 weeks prior to study entry.

- Acute bacterial or viral infection within 4 weeks prior to enrollment.

- Received an immunization within 4 weeks prior to enrollment.

- History of autoimmune disease including psoriasis, inflammatory bowel disease.

- Medical history of transplantation (solid organ or bone marrow).

- Received an investigational drug in the past 30 days other than Food and Drug Administration (FDA) sanctioned treatment IND antiretroviral agents.

- Renal insufficiency with a serum creatinine level greater than 1.5 times the upper limit of normal.

- Bone marrow suppression as defined by one or more of the following: granulocyte count less than 1,000 cells/µL; hemoglobin less than 9.0g (females) or less than 9.5g (males); or platelet count less than 75,000 cells/µL.

- Evidence of hepatic disease indicated by one or more of the following: SGOT (AST) and/or SGPT (ALT) greater than 5 times the upper limit of normal. Bilirubin greater than 2 times the upper limit of normal (except for patients with known Gilbert's syndrome or those receiving indinavir who may be enrolled if the serum bilirubin is less than or equal to 5 times the upper limit of normal).

- Active cardiac disease (coronary artery disease, congestive heart failure or cardiomyopathy) requiring treatment with any of the following medications: antiarrhythmic agents including digitalis, anti-anginal drugs including topical or systemic nitrates, calcium channel blockers, and beta blockers, and afterload reducers including ACE inhibitors. Patients requiring any of these medications solely for the treatment of hypertension remain eligible for the study.

- Presence of significant cardiac insufficiency (greater than or equal to New York Heart Association Grade 2).

- Diagnosis of an active malignancy requiring treatment with systemic cytotoxic chemotherapy.

- Active alcohol or substance abuse which, in the opinion of the investigator, will seriously compromise the subject's ability to adhere with the demands of the study.

- Any central nervous system (CNS) disease that requires active treatment with anticonvulsants.

- Use of an antimetabolite such as hydroxyurea within 4 weeks prior to study entry.

- Known co-infection with Hepatitis B or C virus unless serum transaminases are less than or equal to 2 times the upper limit of normal on at least two occasions within 8 weeks prior to study entry.

- Known CD4 Nadir less than 50 cells/mm(3).

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: No

Insgesamt offiziell
Nachname Rolle Zugehörigkeit
Bayer Study Director Study Director Bayer
Ort
Einrichtung:
| Birmingham, Alabama, 35294, United States
| Davis, California, 95616, United States
| Los Angeles, California, 90095, United States
| Palo Alto, California, 94304-1207, United States
| San Francisco, California, 94115, United States
| Chicago, Illinois, 60611-2908, United States
| Chicago, Illinois, 60612, United States
| Bethesda, Maryland, 20892, United States
| Cleveland, Ohio, 44106-2602, United States
| Creteil, 94010, France
| London, Greater London, SW10 9NH, United Kingdom
Standort Länder

France

United Kingdom

United States

Überprüfungsdatum

December 2014

Verantwortliche Partei

Art: Sponsor

Schlüsselwörter
Hat den Zugriff erweitert No
Bedingung Durchsuchen
Anzahl der Waffen 2
Armgruppe

Etikette: Arm 1

Art: Experimental

Etikette: Arm 2

Art: Active Comparator

Studiendesign Info

Zuweisung: Randomized

Interventionsmodell: Parallel Assignment

Hauptzweck: Treatment

Maskierung: Double

Quelle: ClinicalTrials.gov